MX2016000384A - Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. - Google Patents
Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.Info
- Publication number
- MX2016000384A MX2016000384A MX2016000384A MX2016000384A MX2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A
- Authority
- MX
- Mexico
- Prior art keywords
- vegf antagonist
- treating
- chorioretinal neovascular
- child
- permeability disorders
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 6
- 230000035699 permeability Effects 0.000 title abstract 3
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 abstract 1
- 229940012356 eye drops Drugs 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001839 systemic circulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F9/00821—Methods or devices for eye surgery using laser for coagulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere al uso de un antagonista de VEGF en el tratamiento de trastornos neovasculares o permeabilidad coriorretiniana en los niños. En particular, la presente invención proporciona un antagonista de VEGF para su uso en un método para tratar a un niño que tiene CNV o ME, en el que dicho método comprende la administración al ojo de un niño un antagonista de VEGF que, o bien no alcanza, o se elimina rápidamente de la circulación sistémica. El antagonista de VEGF puede ser administrado por vía intravítrea, por ejemplo, a través de inyección, o por vía tópica, por ejemplo, en forma de gotas para los ojos. La presente invención proporciona además el uso de un antagonista de VEGF en la fabricación de un medicamento para tratar a un niño que tiene un trastorno neovascular o permeabilidad coriorretiniana.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845064P | 2013-07-11 | 2013-07-11 | |
| PCT/IB2014/062978 WO2015004616A1 (en) | 2013-07-11 | 2014-07-09 | Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016000384A true MX2016000384A (es) | 2016-04-29 |
Family
ID=51211282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016000384A MX2016000384A (es) | 2013-07-11 | 2014-07-09 | Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160168240A1 (es) |
| EP (1) | EP3019526A1 (es) |
| JP (1) | JP2016528202A (es) |
| KR (1) | KR20160029794A (es) |
| CN (1) | CN105377891A (es) |
| AU (2) | AU2014288837A1 (es) |
| BR (1) | BR112016000177A2 (es) |
| CA (1) | CA2917807A1 (es) |
| MX (1) | MX2016000384A (es) |
| RU (1) | RU2676274C2 (es) |
| WO (1) | WO2015004616A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5166398B2 (ja) | 2006-04-07 | 2013-03-21 | エアーピオ セラピューティクス インコーポレイテッド | ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用 |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| JP5536113B2 (ja) | 2009-07-06 | 2014-07-02 | アケビア セラピューティクス インコーポレイテッド | がん細胞の転移を予防するための化合物、組成物および方法 |
| EP3505182A1 (en) | 2011-10-13 | 2019-07-03 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
| US20170232199A1 (en) * | 2014-05-12 | 2017-08-17 | Formycon Ag | Pre-Filled Plastic Syringe Containing a VEGF Antagonist |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| MY194736A (en) | 2015-09-23 | 2022-12-15 | Aerpio Therapeutics Inc | Methods of treating intraocular pressure with activators of tie-2 |
| MX2018006171A (es) * | 2015-11-18 | 2018-12-19 | Formycon Ag | Jeringa de plastico precargada que contiene un antagonista de vegf. |
| WO2017084616A1 (en) * | 2015-11-19 | 2017-05-26 | Zhuhai Tairuishang Biopharm Ltd. | Methods and compositions for binding vegf |
| CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
| CN109310756B (zh) * | 2016-05-13 | 2022-06-28 | 奥美药业有限公司 | 新型血管生成素2，vegf双特异性拮抗剂 |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| EP3573641A4 (en) * | 2017-01-25 | 2020-11-11 | Iconic Therapeutics, Inc. | TREATMENT METHODS FOR DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION |
| SG11201909214YA (en) * | 2017-05-01 | 2019-11-28 | Ojai Retinal Technology Llc | System and process for treatment of myopia |
| AU2018370135A1 (en) * | 2017-11-16 | 2020-06-04 | Iveric Bio, Inc. | A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (IPCV) |
| WO2019169341A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| US11253502B2 (en) | 2019-04-29 | 2022-02-22 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the Schlemm's canal |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021123142A1 (en) * | 2019-12-19 | 2021-06-24 | Active Biotech Ab | Compounds for treatment of eye diseases associated with excessive vascularisation |
| RU2762991C1 (ru) * | 2021-09-06 | 2021-12-24 | федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения макулярного отека вследствие окклюзии ветви центральной вены сетчатки в сочетании с ретинальной артериолярной макроаневризмой |
| TW202525324A (zh) * | 2023-08-17 | 2025-07-01 | 大陸商信達生物製藥（蘇州）有限公司 | 治療年齡相關性黃斑變性和糖尿病性黃斑水腫的方法 |
| CN118085112B (zh) * | 2024-04-29 | 2024-08-09 | 上海鼎新基因科技有限公司 | 抗多个vegf家族蛋白的融合蛋白及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7883717B2 (en) | 2001-06-12 | 2011-02-08 | Johns Hopkins University | Reservoir device for intraocular drug delivery |
| WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| WO2005121176A1 (en) | 2004-06-08 | 2005-12-22 | Chengdu Kanghong Biotechnologies Co. Ltd | Angiogenesis-inhibiting chimeric protein and the use |
| US20070072933A1 (en) * | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an ocular agent |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| CN101965183A (zh) * | 2008-02-21 | 2011-02-02 | 伊斯塔药品公司 | 作为佐剂的眼用nsaid |
| CN102215875B (zh) * | 2008-10-16 | 2014-08-06 | 凯瑟琳·科根·法瑞纳斯 | 持续药物递送系统 |
| BRPI0921469B1 (pt) | 2008-11-03 | 2022-01-18 | Molecular Partners Ag | Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica |
| US9226917B2 (en) * | 2008-12-16 | 2016-01-05 | Valeant Pharmaceuticals International, Inc. | Photodynamic therapy for conditions of the eye |
| SG2014007389A (en) | 2009-01-29 | 2014-04-28 | Forsight Vision4 Inc | Posterior segment drug delivery |
| JP2012525415A (ja) * | 2009-05-01 | 2012-10-22 | オプソテツク・コーポレイシヨン | 眼科疾患を処置または予防するための方法 |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| RU2469734C2 (ru) * | 2010-09-02 | 2012-12-20 | Григорий Владимирович Пантелеев | Лечебное средство для лечения расстройств аккомодаций "stiak" |
-
2014
- 2014-07-09 RU RU2016104397A patent/RU2676274C2/ru not_active IP Right Cessation
- 2014-07-09 US US14/903,749 patent/US20160168240A1/en not_active Abandoned
- 2014-07-09 BR BR112016000177A patent/BR112016000177A2/pt not_active IP Right Cessation
- 2014-07-09 AU AU2014288837A patent/AU2014288837A1/en not_active Abandoned
- 2014-07-09 WO PCT/IB2014/062978 patent/WO2015004616A1/en not_active Ceased
- 2014-07-09 CN CN201480039606.4A patent/CN105377891A/zh active Pending
- 2014-07-09 MX MX2016000384A patent/MX2016000384A/es unknown
- 2014-07-09 KR KR1020167000239A patent/KR20160029794A/ko not_active Withdrawn
- 2014-07-09 EP EP14741406.4A patent/EP3019526A1/en not_active Withdrawn
- 2014-07-09 CA CA2917807A patent/CA2917807A1/en not_active Abandoned
- 2014-07-09 JP JP2016524930A patent/JP2016528202A/ja active Pending
-
2017
- 2017-06-09 AU AU2017203923A patent/AU2017203923B2/en not_active Ceased
-
2018
- 2018-02-27 US US15/906,421 patent/US20180194835A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014288837A1 (en) | 2015-12-10 |
| CA2917807A1 (en) | 2015-01-15 |
| RU2676274C2 (ru) | 2018-12-27 |
| AU2017203923B2 (en) | 2018-10-18 |
| KR20160029794A (ko) | 2016-03-15 |
| EP3019526A1 (en) | 2016-05-18 |
| WO2015004616A1 (en) | 2015-01-15 |
| RU2016104397A (ru) | 2017-08-16 |
| CN105377891A (zh) | 2016-03-02 |
| US20160168240A1 (en) | 2016-06-16 |
| RU2016104397A3 (es) | 2018-05-31 |
| BR112016000177A2 (pt) | 2017-12-12 |
| AU2017203923A1 (en) | 2017-07-06 |
| US20180194835A1 (en) | 2018-07-12 |
| JP2016528202A (ja) | 2016-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016000384A (es) | Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. | |
| MX2016000385A (es) | Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad. | |
| JP2012046524A5 (es) | ||
| WO2014184576A3 (en) | Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| MY199027A (en) | Method for treating or preventing ophthalmological conditions | |
| BR112018069789A2 (pt) | medicamento obtido pela combinação do agonista de fxr e arb | |
| MX2020012924A (es) | Terapias combinadas de coenzima q10 para el tratamiento de cancer. | |
| BR112015025955A2 (pt) | tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação | |
| MX2016002645A (es) | Tratamiento combinado para tratar el glioblastoma. | |
| HK1211525A1 (en) | Laquinimod and pridopidine for treating neurodegenerative disorders | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| MX373851B (es) | Métodos de administración de tratamiento con pirfenidona. | |
| MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
| HK1209341A1 (zh) | 與治療柏金遜症相關之運動與動作障礙副作用之治療 | |
| FI3445351T3 (fi) | Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen | |
| MX2016000220A (es) | Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp. | |
| PL3370693T3 (pl) | Ulepszone preparaty lewosimendanu do podawania dożylnego w postaci roztworów do wlewów lub wstrzykiwań i koncentratu do wlewów | |
| WO2015031598A3 (en) | Therapeutic dnp derivatives and methods using same | |
| MX2020004106A (es) | Metodo de tratamiento de trastornos neurodegenerativos. | |
| GB201518170D0 (en) | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent | |
| AR102494A1 (es) | Métodos para tratar enfermedades oculares | |
| PH12014502497A1 (en) | New treatments of hepatitis c virus infection | |
| WO2014149998A8 (en) | Systemic administration of androgen in treating dry eye syndrome |